Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis

Inclusion Criteria:

1. Aged 18-65, male or female.

2. The diagnosis of plaque psoriasis vulgaris was in accordance with the westerndiagnostic criteria

3. Conformed to the TCM syndrome differentiation standard of plaque psoriasis withBlood-heat syndrome.

4. At screening period: 3 ≤PASI≤ 20, 3%≤BSA≤ 10% and sPGA≥2.

5. Willing to participate voluntarily and sign a written informed consent.

Exclusion Criteria:

1. Psoriasis caused by drug-induced factors; combined with non-plaque Psoriasis atscreening (such as guttate,arthropathica, pustular, erythrodermic and other types ofPsoriasis); The skin lesions are exclusively observed in subjects with specificareas such as the face, scalp, nails, skin folds, glans penis, mucous membranes,palms, and soles.

2. Systemic therapy with non-biological drugs within 4 weeks prior to randomization,including but not limited to systemic corticosteroids, retinoids, methotrexate, andcyclosporine.

3. Systemic therapy with biological drugs within 12 weeks or 5 half-lives (whichever islonger) prior to randomization, including but not limited to interleukin antibodies (such as ustekinumab, secukinumab) and tumor necrosis factor-alpha antagonists (suchas etanercept, infliximab, adalimumab) in the study.

4. Topical anti-psoriatic treatment received within 2 weeks prior to randomization,including retinoids, vitamin D3 derivatives, corticosteroids, and others

5. Physical therapy received within the 4 weeks prior to randomization, includingphototherapy (such as UVB, PUVA), combination phototherapy, and balneotherapy.

6. Systemic anti-infective treatment received within the 4 weeks prior torandomization; presence of recurrent, chronic, or active infection at baseline asdetermined by the investigator and judged to increase the subject's risk.

7. With a serious, progressive, or uncontrolled disease, including but not limited to adisease of the immune (such as rheumatoid arthritis, systemic lupus erythematosus,and inflammatory bowel disease), endocrine, hematological, urinary, hepatobiliary,and respiratory, nervous, psychiatric, cardiovascular, gastrointestinal, orinfectious system, a malignancy.

8. Patients with serum creatinine above the upper limit of normal at screening, withelevated Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) levels ≥ 1.5 times the upper limit of normal.

9. Participation in other clinical trials and received investigational drugs within 1month prior to screening.

10. Patients with hypersensitivity to the investigational drug components.

11. Patients had a history of smoking, alcohol, drug abuse.

12. Patients (including partners) have plans to become pregnant from 2 weeks before thefirst dose to 1 month after the last dose and Subjects do not take effectivecontraceptive measures during this period or during pregnancy or breastfeeding

13. Any other situation that the investigator did not consider suitable forparticipation in the study, such as other skin problems that hinder the assessmentof Psoriasis, potential compliance problems, inability to complete all examinationsand evaluations in accordance with the protocol requirements, may pose anuncontrollable risk for participation in the study.